A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hee Seung | - |
dc.contributor.author | Chung, Moon Jae | - |
dc.contributor.author | Park, Jeong Youp | - |
dc.contributor.author | Bang, Seungmin | - |
dc.contributor.author | Park, Seung Woo | - |
dc.contributor.author | Kim, Ho Gak | - |
dc.contributor.author | Noh, Myung Hwan | - |
dc.contributor.author | Lee, Sang Hyub | - |
dc.contributor.author | Kim, Yong-Tae | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Kim, Chang Duck | - |
dc.contributor.author | Lee, Dong Ki | - |
dc.contributor.author | Cho, Kwang Bum | - |
dc.contributor.author | Cho, Chang Min | - |
dc.contributor.author | Moon, Jong Ho | - |
dc.contributor.author | Kim, Dong Uk | - |
dc.contributor.author | Kang, Dae Hwan | - |
dc.contributor.author | Cheon, Young Koog | - |
dc.contributor.author | Choi, Ho Soon | - |
dc.contributor.author | Kim, Tae Hyeon | - |
dc.contributor.author | Kim, Jae Kwang | - |
dc.contributor.author | Moon, Jieun | - |
dc.contributor.author | Shin, Hye Jung | - |
dc.contributor.author | Song, Si Young | - |
dc.date.available | 2020-11-02T09:41:07Z | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.issn | 1536-5964 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/5378 | - |
dc.description.abstract | Background: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. Methods: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in South Korea between 2007 and 2011. Patients were randomly assigned to receive GemCap (oral capecitabine 1660mg/m(2) plus Gem 1000mg/m(2) by 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break every 4 weeks) or Gem (by 30-minute intravenous infusion weekly for 3 weeks every 4 weeks). Results: Median overall survival (OS) time, the primary end point, was 10.3 and 7.5 months in the GemCap and Gem arms, respectively (P=0.06). Progression-free survival was 6.2 and 5.3 months in the GemCap and Gem arms, respectively (P=0.08). GemCap significantly improved overall response rate compared with Gem alone (43.7% vs 17.6%; P=0.001). Overall frequency of grade 3 or 4 toxicities was similar in each group. Neutropenia was the most frequent grade 3 or 4 toxicity in both groups. Conclusion: GemCap failed to improve OS at a statistically significant level compared to Gem treatment. This study showed a trend toward improved OS compared to Gem alone. GemCap and Gem both exhibited similar safety profiles. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1097/MD.0000000000005702 | - |
dc.identifier.scopusid | 2-s2.0-85013838830 | - |
dc.identifier.wosid | 000392083900026 | - |
dc.identifier.bibliographicCitation | MEDICINE, v.96, no.1 | - |
dc.citation.title | MEDICINE | - |
dc.citation.volume | 96 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | COOPERATIVE-ONCOLOGY-GROUP | - |
dc.subject.keywordPlus | PLUS CAPECITABINE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | STATISTICS | - |
dc.subject.keywordAuthor | capecitabine | - |
dc.subject.keywordAuthor | gemcitabine | - |
dc.subject.keywordAuthor | overall survival | - |
dc.subject.keywordAuthor | pancreatic cancer | - |
dc.subject.keywordAuthor | progression-free survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.